The ESSENCE Trial (Newsome 2024, NEJM, N=800) Showed That Semaglutide 2.4mg Achieved MASH Resolution Without Worsening Fibrosis in 62.9% of Patients vs 18.6% on Placebo — the Largest Histological Improvement Ever Seen in a Fatty Liver Drug Trial — Establishing GLP-1 Receptor Agonists as a First-Line Option for MASLD/MASH via Multiple Hepatic Mechanisms Far Beyond Weight Loss

the landmark result: Newsome PN et al. (2024, New England Journal of Medicine): ESSENCE (Efficacy and Safety of Semaglutide in Patients with Non-alcoholic Steatohepatitis); DESIGN: phase 3, double-blind, randomized, placebo-controlled; N=800 adults with biopsy-proven MASH (confirmed histologically: steatosis ≥10%, hepatocyte ballooning, lobular inflammation) AND fibrosis stages F2 (perisinusoidal and portal/periportal) or F3 (bridging fibrosis); patients did NOT have cirrhosis (F4 excluded); INTERVENTION: subcutaneous semaglutide 2.4mg weekly (Wegovy dose — the obesity indication dose, NOT the 1mg Ozempic diabetes dose) vs placebo; escalation over 16 weeks to target 2.4mg; background: lifestyle counseling for all; duration: 72 weeks; PRIMARY ENDPOINT 1: MASH resolution without worsening of fibrosis (histological; defined as NAS ≥4 with reduction → ≤3, or steatohepatitis no longer present, without fibrosis stage increase); RESULT: 62.9% semaglutide vs 18.6% placebo (p < 0.001; OR 7.6); PRIMARY ENDPOINT 2: liver fibrosis improvement by ≥1 stage without worsening of MASH; RESULT: 36.8% semaglutide vs 22.4% placebo (p < 0.001); KEY SECONDARY ENDPOINTS: ALT normalization: significant (specific numbers vary by cut-off); body weight reduction: −10.5% semaglutide vs −2.0% placebo at 72 weeks; liver fat (MRI-PDFF): −31.5 percentage points semaglutide vs −4.1 placebo; liver stiffness (MRE): significant reduction; SAFETY: nausea (44.4% vs 15.9%) and vomiting (19.5% vs 5.5%) as expected with semaglutide; no serious hepatic adverse events attributable to semaglutide; SIGNIFICANCE: the 62.9% MASH resolution rate is the highest ever reported in a phase 3 MASH drug trial; for context, resmetirom's STELLAR trial achieved 25.9% (low dose) and 29.9% (high dose) MASH resolution — the ESSENCE result is roughly 2× the resmetirom effect size (noting these trials are not directly comparable — different populations, different endpoints, different fibrosis stage inclusion)

why GLP-1 protects the liver beyond weight loss: GLP-1 receptor agonists produce substantial liver benefits through multiple mechanisms that are partially independent of weight loss — evidenced by the fact that the fibrosis improvement (36.8%) is greater than what weight loss alone would predict for the degree of weight loss achieved; MECHANISM 1 — DIRECT HEPATIC GLP-1 RECEPTOR SIGNALING: GLP-1R is expressed on human hepatocytes (though at lower levels than in the pancreas and gut); hepatic GLP-1R activation: inhibits de novo lipogenesis (DNL — the synthesis of new fat from glucose/fructose in the liver) by downregulating SREBP-1c (Sterol Regulatory Element-Binding Protein 1c, the master transcription factor for lipogenic genes including FAS, ACC1, SCD-1); reduces VLDL-triglyceride secretion; activates AMPK (AMP-activated kinase) → inhibits acetyl-CoA carboxylase (ACC) → reduces malonyl-CoA → permits carnitine palmitoyltransferase 1 (CPT1) activity → increased mitochondrial fatty acid β-oxidation; MECHANISM 2 — GLP-1R ON KUPFFER CELLS: Kupffer cells are the liver's resident macrophages; they initiate and perpetuate hepatic inflammation in MASH (activated by lipopolysaccharide from gut-derived LPS, by free fatty acids, and by damaged hepatocyte danger signals); GLP-1R on Kupffer cells: reduces NF-κB activation → decreased secretion of TNF-α, IL-6, IL-1β, MCP-1; reduces TGF-β1 secretion (the primary driver of hepatic stellate cell activation and fibrosis); MECHANISM 3 — GLP-1R ON HEPATIC STELLATE CELLS (HSC): HSCs are the primary producers of collagen in liver fibrosis; GLP-1R on HSC: reduces activation (reduces conversion to myofibroblast phenotype); reduces collagen type I and III secretion; promotes HSC apoptosis; this may explain fibrosis regression; MECHANISM 4 — INDIRECT: weight loss → reduced adipose tissue lipolysis → reduced free fatty acid delivery to liver → reduced substrate for de novo lipogenesis and triglyceride esterification → reduced hepatic fat; improved insulin sensitivity → reduced hepatic insulin resistance → less lipogenic signaling; improved gut microbiome → reduced LPS leakage → reduced Kupffer cell activation

STELLAR trial and the first approved MASH drug: RESMETIROM (Rezdiffra, MSD/Madrigal Pharmaceuticals): FDA approved March 2024 as the first drug specifically indicated for MASH with moderate-to-advanced fibrosis (F2-F3 in adults with MASLD); mechanism: selective thyroid hormone receptor-β (THR-β) agonist; THR-β is expressed predominantly in the liver; thyroid hormone receptor activation in the liver: increases mitochondrial biogenesis and fatty acid oxidation; reduces de novo lipogenesis (suppresses SREBP-1c independently); reduces LDL-C and non-HDL-C (significant lipid benefit); does not cause cardiac or bone effects (THR-β vs THR-α selectivity: thyroid's cardiac effects are mediated by THR-α, which resmetirom spares); STELLAR TRIAL (2023, NEJM; Harrison SA et al.): N=966, biopsy-proven MASH with F1b-F3 fibrosis; resmetirom 80mg: 25.9% MASH resolution vs 9.7% placebo; resmetirom 100mg: 29.9% vs 9.7% placebo; fibrosis improvement ≥1 stage (primary endpoint shared with ESSENCE): 24.2% (80mg) and 25.9% (100mg) vs 14.2% placebo; DIRECT COMPARISON CAVEATS: ESSENCE vs STELLAR cannot be directly compared — different drug, different patient populations, different baseline fibrosis distribution, different timing; ESSENCE's 62.9% vs STELLAR's 25.9–29.9% MASH resolution appears dramatically different but the populations are not identical; the ESSENCE trial required F2-F3 fibrosis; STELLAR included F1b (most lenient); COMBINATION THERAPY TRIALS UNDERWAY: given the different mechanisms of GLP-1 (weight loss, gut-liver axis, GLP-1R direct signaling) vs resmetirom (THR-β direct hepatic action), combination therapy is being studied; early results suggest additive or potentially synergistic histological benefit; this combination may become the standard of care for advanced MASH in the next few years

who needs treatment and how to diagnose it: MASLD DIAGNOSTIC CRITERIA (2023 consensus): MASLD = hepatic steatosis (>5% of hepatocytes containing fat on biopsy, OR >5% liver fat on MRI-PDFF, OR controlled attenuation parameter [CAP] score >275 dB/m on FibroScan) PLUS at least one cardiometabolic risk factor (BMI >25, T2DM or pre-diabetes, elevated TG/low HDL, hypertension); MASH = MASLD with histological inflammation and hepatocyte ballooning (requires biopsy for definitive diagnosis); FIBROSIS STAGING: F0: no fibrosis; F1a: mild perisinusoidal fibrosis (zone 3); F1b: portal/periportal fibrosis; F1c: both 1a and 1b; F2: perisinusoidal AND portal/periportal fibrosis; F3: bridging fibrosis; F4: cirrhosis; THE FIBROSIS PROGNOSTIC CLIFF: patients with F0-F1 have similar liver-related mortality to the general population; F2-F3 have 5–10× higher liver-related mortality; F4 (cirrhosis) has 20–50× higher mortality; TREATMENT THRESHOLD: current AASLD (2024) and European EASL (2024) guidance: consider pharmacological therapy in patients with MASH + ≥F2 fibrosis; lifestyle intervention alone recommended for F0-F1 MASH; NON-INVASIVE ALTERNATIVES TO BIOPSY: liver biopsy remains the gold standard but is invasive and costly; validated non-invasive alternatives: FIB-4 score (age × ALT / [platelet count × √AST]): FIB-4 <1.30 = low risk; >2.67 = high risk; MRE (magnetic resonance elastography): best non-invasive fibrosis staging (kPa); fibroscan (VCTE) + CAP: widely available; useful for both steatosis (CAP) and fibrosis (kPa); ASAT (agile steatohepatitis score): newer biomarker panel; who to screen: all adults with obesity (BMI >30), T2DM, or metabolic syndrome should be evaluated with FIB-4 and liver ultrasound; GLP-1 drug therapy is appropriate for those with MASH + ≥F2 on biopsy or high-probability non-invasive testing